Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: A randomized clinical trial

Archives of Gynecology and Obstetrics

Volumn 290, Issue 2, 2014, Pages 321-328

  Kahraman, Korhan ^a   Şükür, Yavuz Emre ^a   Atabekoǧlu, Cem Somer ^a   Ateş, Can ^a   Taşkin, Salih ^a   Çetinkaya, Şerife Esra ^a   Tolunay, Harun Egemen ^a   Özmen, Batuhan ^a   Sönmezer, Murat ^a   Berker, Bülent ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Hirsutism; Hyperandrogenism; Insulin resistance; Oral contraceptive; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DROSPIRENONE; ETHINYLESTRADIOL; PRASTERONE SULFATE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; BREAST TENDERNESS; CARBOHYDRATE METABOLISM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRIMAN GALLWEY SCORE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; NAUSEA; ORAL CONTRACEPTIVE USE; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; WAIST HIP RATIO;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENES; BIOLOGICAL MARKERS; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CONTRACEPTIVES, ORAL, COMBINED; CYPROTERONE ACETATE; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPIDS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; TURKEY; WAIST-HIP RATIO;

EID: 84904541540     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3217-5     Document Type: Article

References (44)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbons: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011 (Pubitemid 30644187)
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749 (Pubitemid 38766360)
3. Dunaif A (2011) Polycystic ovary syndrome in 2011: genes, aging and sleep apnea in polycystic ovary syndrome. Nat Rev Endocrinol 20:72-74
4. Creatsas G, Koliopoulos C, Mastorakos G (2000) Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 900:245-252 (Pubitemid 30251475)
5. Balen A (2004) The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 18:685-706
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174 (Pubitemid 19250404)
7. Utiger RD (1996) Insulin and the polycystic ovary syndrome. New Engl J Med 335:657-658
8. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A et al (1996) Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol Oxf 44:277-284 (Pubitemid 26063404)
9. Wild RA (1995) Obesity, lipids, cardiovascular disease and androgen excess. Am J Med 98:275-325
10. Kasdorf G, Kalkhoff RK (1988) Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab 66:846-852
11. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V (1992) Insulin resistance, secretion and metabolism in users of oral contraception. J Clin Endocrinol Metab 74:64-70
12. Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA (1990) Effect of low dose oral contraceptive on gonadotrophins, androgens and sex hormone binding globulin in nonhirsute women. Fertil Steril 53:35-39 (Pubitemid 20041312)
13. Hillard PJ (2005) Oral contraceptives and the management of hyperandrogenism - polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am 34:707-723
14. Buggs C, Rosenfield RL (2005) Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 34:677-705 (Pubitemid 41112093)
15. Archer JS, Chang RJ (2004) Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18:737-754 (Pubitemid 40424608)
16. Azziz R, Carmina E, Dewaily D, Diamanti-Kandarakis E, Escobar- Morreale HF, Hutterweit W (2006) Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237-4245 (Pubitemid 44833391)
17. Azziz R (2003) The evaluation and management of hirsutism. Obstet Gynecol 101:995-1007
18. Hintze, J (2001) PASS 11. NCSS, LLC. Kaysville, Utah, USA. http://www.ncss.com
19. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2005) Guidance for industry; acne vulgaris: developing drugs for treatment. Rockville, MD
20. Batukan C, Muderris II, Ozcelik B, Ozturk A (2007) Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 23:38-44
21. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL et al (2008) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1105-1120 (Pubitemid 351519694)
22. Conn JJ, Jacobs HS (1997) The clinical management of hirsutism. Eur J Endocrinol 136:339-348 (Pubitemid 27207137)
23. Krattenmacher R (2000) Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62:29-38
24. Rittmaster RS (1995) Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 80:2559-2563
25. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R et al (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817-2823 (Pubitemid 38766371)
26. Bhattacharya SM, Jha A (2012) Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 98:1053-1059
27. Batukan C, Muderris II (2006) Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long term treatment of hirsutism. Fertil Steril 85:436-440 (Pubitemid 43170919)
28. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC (2010) Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 82:139-146
29. Falsetti L, Galbignani E (1990) Long-term treatment with the combination ethinyl estradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 42:611-619
30. Golland IM, Elstein ME (1993) Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 687:263-271 (Pubitemid 23217946)
31. Wiebe RH, Morris CV (1984) Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 63:12-14 (Pubitemid 14221911)
32. .Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamant-Kandarakis E, Creatsas G (2006) Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 85:420-427 (Pubitemid 43170917)
33. .Cagnacci A, Paoletti AM, Renzi A, Orru M, Pilloni M, Melis GB et al (2003) Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 88:3621-3625 (Pubitemid 37034504)
34. .Halperin IJ, Kumar SS, Stroup DF, Laredo SE (2011) The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod 26:191-201
35. .Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59:141-154 (Pubitemid 38140845)
36. .Mastorakos G, Koliopoulos C, Creatsas G (2002) Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 77:919-927 (Pubitemid 34497157)
37. Klipping C, Marr J (2005) Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71:409-416 (Pubitemid 40725775)
38. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995) Effects of new oral contraceptive containing an antimineralocorticoid progestogen drospirenone on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 80:1816-1821
39. .Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S (2008) Effects of third-generation oral contraceptives on highsensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 111:857-864 (Pubitemid 351482617)
40. .Kilic S, Yilmaz N, Zulfikaroglu E, Erdogan G, Aydin M, Batioglu S (2011) Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecol Endocrinol 27:622-629
41. .Norouzi V, Seifi M, Fallah S, Korani M, Samadikuchaksaraei A (2011) Effect of oral contraceptive therapy on homocysteine and C-reactive protein levels in women: an observational study. Anadolu Kardiyol Derg 11:698-702
42. .Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A (2006) Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception 73:348-351 (Pubitemid 43375092)
43. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R et al (2012) Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS consensus workshop group. Fertil Steril 97:28-38
44. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JAC (2013) Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 185:E115-E120